A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
Solid Tumors
DRUG: INCB001158|DRUG: Epacadostat|DRUG: Pembrolizumab
Phase 1 Only: Safety and Tolerability of INCB001158 in Combination With Epacadostat ± Pembrolizumab as Assessed by Number of Participants With a Treatment-emergent Adverse Event (TEAE), TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment., Up to approximately 12 months per subject|Phase 2 Only: Objective Response Rate (ORR) of INCB001158 in Combination With Epacadostat ± Pembrolizumab, Defined as percentage of subjects having a complete response (CR) or partial response (PR) based on investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)., Up to approximately 12 months per subject
Phase 2 Only: Safety and Tolerability of INCB001158 in Combination With Epacadostat ± Pembrolizumab as Assessed by Number of Participants With a TEAE, TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment., Up to approximately 12 months per subject|Phase 1 Only: ORR With INCB001158 in Combination With Epacadostat ± Pembrolizumab, Defined as percentage of subjects having a CR or PR based on investigator assessment per RECIST v1.1., Up to approximately 12 months per subject|Disease Control Rate With INCB001158 in Combination With Epacadostat ± Pembrolizumab, Defined as percentage of subjects having CR, PR, or stable disease for at least 56 days based on investigator assessment per RECIST v1.1., Up to approximately 12 months per subject|Duration of Response With INCB001158 in Combination With Epacadostat ± Pembrolizumab, Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression., Up to approximately 12 months per subject|Progression-free Survival With INCB001158 in Combination With Epacadostat ± Pembrolizumab, Defined as the time from date of first dose of study treatment until the earliest date of disease progression (based on investigator assessment of per RECIST v1.1) or death due to any cause, if occurring sooner than progression., Up to approximately 12 months per subject|Plasma Pharmacokinetic Profile of INCB001158 and Epacadostat, Noncompartmental method of analysis will be used to analyze the plasma concentrations of INCB001158 and epacadostat., Up to approximately 1 month
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.